Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In May 2024, Lycia Therapeutics completed a $106.6 million Series C financing to advance its pipeline of LYTAC extracellular protein degraders to the clinic. Lycia is headquartered in South San Francisco.
The role:
The Sr. Director / Exec. Director, Program Management supports drug development programs to drive program strategy and execution. In partnership with the Project Team Lead, the Sr. Director / Exec. Director, Program Management integrates diverse perspectives to create comprehensive product plans and ensure that key deliverables are met on time, within budget, and with high-quality results. The successful candidate demonstrates outstanding influencing and communication skills and has a solution-oriented mindset to move programs forward with a sense of urgency.